Tekla Life Sciences Investors is a closed-ended equity mutual fund launched and managed by Tekla Capital Management LLC. The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management industries. The fund primarily invests in growth stocks of small cap companies. It employs fundamental analysis with a focus on factors such as market position for services or products, experience of business management, technological expertise, and the ability either to generate funds internally to finance growth or to secure outside sources of capital to create its portfolio. The fund benchmarks the performance of its portfolio against the NASDAQ Biotech Index and the S&P 500 Index. It was formerly known as H&Q Life Sciences Investors fund. Tekla Life Sciences Investors was formed on February 20, 1992 and is domiciled in the United States.
Industry, Sector and Symbol
Stock Exchange NYSE
Industry Investment offices, not elsewhere classified
Sub-IndustryN/A
SectorFinance
Current SymbolNYSE:HQL
Previous Symbol
CUSIPN/A
Phone617-772-8500
Debt
Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A
Miscellaneous
EmployeesN/A
Outstanding Shares22,010,000
Market Cap$385.14 million
OptionableNot Optionable
Tekla Life Sciences Investors (NYSE:HQL) Frequently Asked Questions
What is Tekla Life Sciences Investors' stock symbol?
Tekla Life Sciences Investors trades on the New York Stock Exchange (NYSE) under the ticker symbol "HQL."
How often does Tekla Life Sciences Investors pay dividends? What is the dividend yield for Tekla Life Sciences Investors?
Tekla Life Sciences Investors announced a quarterly dividend on Monday, August 20th. Shareholders of record on Tuesday, August 28th will be given a dividend of $0.40 per share on Friday, September 28th. This represents a $1.60 dividend on an annualized basis and a dividend yield of 9.03%. The ex-dividend date of this dividend is Monday, August 27th. View Tekla Life Sciences Investors' Dividend History.
Has Tekla Life Sciences Investors been receiving favorable news coverage?
Media headlines about HQL stock have been trending somewhat positive recently, according to InfoTrie Sentiment Analysis. InfoTrie identifies positive and negative news coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Tekla Life Sciences Investors earned a media sentiment score of 1.2 on InfoTrie's scale. They also gave headlines about the company a news buzz of 4.0 out of 10, indicating that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the immediate future.
Who are some of Tekla Life Sciences Investors' key competitors?
Some companies that are related to Tekla Life Sciences Investors include Gabelli Equity Trust (GAB), Tri-Continental (TY), PIMCO Corporate&Income Opportunity Fund (PTY), Royce Value Trust (RVT), Tortoise Energy Infrastructure (TYG), Liberty All-Star Equity Fund (USA), Hercules Capital (HTGC), Boulder Growth & Income Fund (BIF), Apollo Investment (AINV), PIMCO High Income Fund (PHK), AllianceBernstein Global Hgh Incm Fd (AWF), General American Investors (GAM), Solar Capital (SLRC), Goldman Sachs BDC (GSBD) and Tekla Healthcare Investors (HQH).
Who are Tekla Life Sciences Investors' key executives?
Tekla Life Sciences Investors' management team includes the folowing people:
- Dr. Daniel R. Omstead M.S, Ph.D., Principal Exec. Officer, Pres and Trustee (Age 65)
- Ms. Laura F. Woodward, Principal Financial Officer, Chief Compliance Officer, Sec. and Treasurer (Age 50)
- Ms. Betty T. Chang, Assistant Treasurer (Age 46)
Who are Tekla Life Sciences Investors' major shareholders?
Tekla Life Sciences Investors' stock is owned by a number of of institutional and retail investors. Top institutional investors include Wells Fargo & Company MN (1.12%), Claraphi Advisory Network LLC (0.30%), Commonwealth Equity Services LLC (0.17%), Private Advisor Group LLC (0.16%), Strategic Wealth Advisors Group LLC (0.06%) and Bank of Montreal Can (0.06%). View Institutional Ownership Trends for Tekla Life Sciences Investors.
Which major investors are selling Tekla Life Sciences Investors stock?
Which major investors are buying Tekla Life Sciences Investors stock?
HQL stock was purchased by a variety of institutional investors in the last quarter, including Wells Fargo & Company MN, Strategic Wealth Advisors Group LLC, Bank of Montreal Can, Wedbush Securities Inc., Claraphi Advisory Network LLC, Parallel Advisors LLC and Private Advisor Group LLC. View Insider Buying and Selling for Tekla Life Sciences Investors.
How do I buy shares of Tekla Life Sciences Investors?
Shares of HQL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Tekla Life Sciences Investors' stock price today?
One share of HQL stock can currently be purchased for approximately $17.72.
How big of a company is Tekla Life Sciences Investors?
Tekla Life Sciences Investors has a market capitalization of $385.14 million.
What is Tekla Life Sciences Investors' official website?
How can I contact Tekla Life Sciences Investors?
Tekla Life Sciences Investors' mailing address is 2 LIBERTY SQUARE 9TH FLOOR, BOSTON MA, 02109. The company can be reached via phone at 617-772-8500 or via email at [email protected]
MarketBeat Community Rating for Tekla Life Sciences Investors (NYSE HQL)
MarketBeat's community ratings are surveys of what our community members think about Tekla Life Sciences Investors and other stocks. Vote "Outperform" if you believe HQL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HQL will underperform the S&P 500 over the long term. You may vote once every thirty days.
